Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESSENCE semaglutide study in non-cirrhotic NASH
jRCT2031210033Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Semaglutide with Placebo (2 arms). Primary endpoints: Part 1: Resolution of steatohepatitis and no worsening of liver fibrosis, Part 1: Improvement in liver fibrosis and no worsening of steatohepatitis and 1 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2031210033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210033.